Evotec SE (XSWX:EVT) Current Accrued Expense: CHF0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:EVT Evotec SE XSWX:EVT
58 GF Score
Price CHF4.63
GF Value CHF8.56
! 4 Warning Signs
View Full Analysis

What is Evotec SE Current Accrued Expense?

Evotec SE XSWX:EVT 58 Current Accrued Expense is CHF0.0 Mil as of Mar. 2026. GuruFocus rates XSWX:EVT with a GF Score™ of 58/100 and a GF Value™ of CHF8.56. The stock has 4 warning signs investors should review.

Evotec SE's Current Accrued Expense for the quarter that ended in Mar. 2026 was CHF0.0 Mil.

Evotec SE Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Evotec SE's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Current Accrued Expense Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Evotec SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:EVT
58GF Score
Evotec SE XSWX:EVT
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of CHF0.0 Mil mean?
Evotec SE (XSWX:EVT) has a Current Accrued Expense of CHF0.0 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Evotec SE and its competitors.
Is Evotec SE's Current Accrued Expense too high?
Evotec SE's current Current Accrued Expense is CHF0.0 Mil. Overall, Evotec SE has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Current Accrued Expense compare to ZTS and UTHR?
Evotec SE's Current Accrued Expense of CHF0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Evotec SE and its competitors. Evotec SE's current Current Accrued Expense is CHF0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Evotec SE (XSWX:EVT) has a current Current Accrued Expense of CHF0.0 Mil. The stock's GF Value™ is CHF8.56, compared to a current price of CHF4.63 — trading 45.9% below its estimated fair value. The current Current Accrued Expense is CHF0.0 Mil. Evotec SE's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Current Accrued Expense is CHF0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (XSWX:EVT) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of CHF4.63 is trading 45.9% below its estimated GF Value™ of CHF8.56.

Key valuation signals for XSWX:EVT:

  • Current Accrued Expense: CHF0.0 Mil
  • GF Value™: CHF8.56 vs. price of CHF4.63 (45.9% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
58GF Score

Get the complete analysis for XSWX:EVT

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF4.63
Price
CHF8.56
GF Value